Revium Rx

Market Movers (8-K)

OID
RVRC
Revium Rx
8-K: Revium Rx Appoints New CFO, Management Shake-up
Revium Rx announced the immediate resignation of CFO Arie Gordashnikov and the appointment of Igor Bluvstein as the new Chief Financial Officer.
OID
RVRC
Revium Rx
8-K: Revium Rx Appoints Permanent CEO and New Chairman
Revium Rx has officially appointed Amir Avraham as permanent CEO and Shlomi Schwartzblat as Chairman of the Board.
Capital raise

Annual Reports (10-K)

OID
RVRC
Revium Rx
10-K: Revium Rx Faces Going Concern Doubt Amidst R&D Losses
Revium Rx, a preclinical biopharmaceutical company, reported a significant net loss of $13.4 million in 2025 and faces substantial doubt about its ability to continue as a going concern, compounded by a dispute over its Nano-Candesartan license.
Delay expected
Capital raise
Worse than expected

New Public Companies (S-1)

OID
RVRC
Revium Rx
S-1/A: Revium Rx Files S-1/A Amendment 5, Details Director Pay
Revium Rx filed an exhibits-only Amendment No. 5 to its S-1 Registration Statement, detailing corporate governance changes and director compensation arrangements.
Capital raise
Delay expected
OID
RVRC
Revium Rx
S-1/A: Revium Rx Files S-1/A for Dual Public & Resale Offering
Revium Rx filed an S-1/A for a self-underwritten public offering of 1.56 million units and a resale of up to 37.6 million common shares by existing stockholders, focusing on lipid-based therapies for antibiotic resistance and cancer.
Delay expected
Worse than expected
Capital raise
OID
RVRC
Revium Rx
S-1/A: Revium Rx Launches IPO Amidst Key Drug Development Delays
Revium Rx, a preclinical biotech firm, is launching a self-underwritten IPO to fund its lipid-based therapies, while facing delays in its lead drug candidates and a dispute over a critical license option.
Worse than expected
Capital raise
Delay expected
OID
RVRC
Revium Rx
S-1/A: Revium Rx Files S-1/A for Nanomedicine IPO Amid Losses
Pre-clinical biotech Revium Rx files an S-1/A for a self-underwritten initial public offering to fund its lipid-based therapies for antibiotic resistance and cancer, despite a history of significant losses.
Worse than expected
Capital raise
Delay expected
OID
RVRC
Revium Rx
S-1/A: Revium Rx. Files S-1/A for Public Offering, Details Biotech Pipeline
Revium Rx., a preclinical biotechnology company, filed an S-1/A for a self-underwritten public offering to fund its advanced lipid-based therapies for antimicrobial resistance and solid tumors.
Delay expected
Worse than expected
Capital raise
OID
RVRC
Revium Rx
S-1: Revium Rx Files for IPO and Resale of Common Stock
Revium Rx, formerly OC Beverages, files an S-1 registration statement for an initial public offering of units and resale of common stock by selling stockholders.
Capital raise